Directly observed antiretroviral therapy eliminates adverse effects of active drug use on adherence

Drug and Alcohol Dependence

Volumn 120, Issue 1-3, 2012, Pages 174-180

  Nahvi, Shadi ^a   Litwin, Alain H ^a   Heo, Moonseong ^a   Berg, Karina M ^a,b   Li, Xuan ^a   Arnsten, Julia H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Directly observed therapy; HIV; Medication adherence; Methadone; Randomized trial; Substance use

Indexed keywords

AMPHETAMINE; ANTIRETROVIRUS AGENT; BENZODIAZEPINE; CANNABIS; COCAINE; METHADONE; OPIATE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ANTI-HIV AGENTS; COCAINE-RELATED DISORDERS; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PREVALENCE; SUBSTANCE-RELATED DISORDERS;

EID: 84155164318     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.07.025     Document Type: Article

References (41)

1. Arnsten J.H., Demas P.A., Grant R.W., Gourevitch M.N., Farzadegan H., Howard A.A., Schoenbaum E.E. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J. Gen. Intern. Med. 2002, 17:377-381.
2. Berg K.M., Demas P.A., Howard A.A., Schoenbaum E.E., Gourevitch M.N., Arnsten J.H. Gender differences in factors associated with adherence to antiretroviral therapy. J. Gen. Intern. Med. 2004, 19:1111-1117.
3. Berg K.M., Litwin A., Li X., Heo M., Arnsten J.H. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011, 113:192-199.
4. Berg K.M., Mouriz J., Li X., Duggan E., Goldberg U., Arnsten J.H. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Contemp. Clin. Trials 2009, 30:481-489.
5. Bradley K.A., Boyd-Wickizer J., Powell S.H., Burman M.L. Alcohol screening questionnaires in women. JAMA 1998, 280:166-171.
6. Brown L.S., Kritz S., Goldsmith R.J., Bini E.J., Robinson J., Alderson D., Rotrosen J. Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep. 2007, 122:441-451.
7. Brown L.S., Kritz S.A., Goldsmith R.J., Bini E.J., Rotrosen J., Baker S., Robinson J., McAuliffe P. Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network. J. Subst. Abuse Treat. 2006, 30:315-321.
8. Chesney M.A., Ickovics J.R., Chambers D.B., Gifford A.L., Neidig J., Zwickl B., Wu A.W. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. AIDS Care 2000, 12:255-266.
9. Conway B., Prasad J., Reynolds R., Farley J., Jones M., Jutha S., Smith N., Mead A., DeVlaming S. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin. Infect. Dis. 2004, 38(Suppl. 5):S402-S408.
10. Cooperman N.A., Parsons J.T., Chabon B., Berg K.M., Arnsten J.H. The development and feasibility of an intervention to improve HAART adherence among HIV-positive patients receiving primary care in methadone clinics. J. HIV/AIDS Soc. Serv. 2007, 6:101-120.
11. Derogatis L.R., Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol. Med. 1983, 13:595-605.
12. DesJarlais D.C., Paone D., Milliken J., Turner C.F., Miller H., Gribble J., Shi Q., Hagan H., Friedman S.R. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 1999, 353:1657-1661.
13. Donny E.C., Brasser S.M., Bigelow G.E., Stitzer M.L., Walsh S.L. Methadone doses of 100mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 2005, 100:1496-1509.
14. Fareed A., Casarella J., Roberts M., Sleboda M., Amar R., Vayalapalli S., Drexler K. High dose versus moderate dose methadone maintenance: is there a better outcome?. J. Addict. Dis. 2009, 28:399-405.
15. Fiellin D.A., Reid M.C., O'Connor P.G. Screening for alcohol problems in primary care: a systematic review. Arch. Intern. Med. 2000, 160:1977-1989.
16. Fisher J.D., Fisher W.A., Amico K.R., Harman J.J. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006, 25:462-473.
17. Gifford A.L., Bormann J.E., Shively M.J., Wright B.C., Richman D.D., Bozzette S.A. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J. Acquir. Immune Defic. Syndr. 2000, 23:386-395.
18. Gordillo V., del Amo J., Soriano V., Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999, 13:1763-1769.
19. Halkitis P.N., Kutnick A.H., Slater S. The social realities of adherence to protease inhibitor regimens: substance use, health care and psychological states. J. Health Psychol. 2005, 10:545-558.
20. Haubrich R.H., Little S.J., Currier J.S., Forthal D.N., Kemper C.A., Beall G.N., Johnson D., Dube M.P., Hwang J.Y., McCutchan J.A. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999, 13:1099-1107.
21. Hinkin C., Barclay T., Castellon S., Levine A., Durvasula R., Marion S., Myers H.F., Longshore D. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007, 11:185-194.
22. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care 2004, 16:199-211.
23. Kapadia F., Vlahov D., Wu Y., Cohen M.H., Greenblatt R.M., Howard A.A., Cook J.A., Goparaju L., Golub E., Richardson J., Wilson T.E. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am. J. Drug Alcohol Abuse 2008, 34:161-170.
24. Kresina T.F., Litwin A., Marion I., Lubran R., Clark H.W. United States government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. J. Drug Policy Anal. 2009, 2:2.
25. Lucas G.M., Cheever L.W., Chaisson R.E., Moore R.D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J. Acquir. Immune Defic. Syndr. 2001, 27:251-259.
26. Lucas G.M., Mullen B.A., Weidle P.J., Hader S., McCaul M.E., Moore R.D. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin. Infect. Dis. 2006, 42:1628-1635.
27. Lucas G.M., Weidle P.J., Hader S., Moore R.D. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin. Infect. Dis. 2004, 38(Suppl. 5):S409-S413.
28. Macalino G.E., Celentano D.D., Latkin C., Strathdee S.A., Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ. Prev. 2002, 14:367-378.
29. Malta M., Magnanini M., Strathdee S., Bastos F. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010, 14:731-747.
30. Maxwell S., Shinderman M. Optimizing response to methadone maintenance treatment: use of higher-dose methadone. J. Psychoactive Drugs 1999, 31:95-102.
31. Mizuno, Y., Purcell, D.W., Mackenzie, S., Tobin, K.E., Wunch, T., Arnsten, J.H., Metsch, L.R., for the INSPIRE Study Team, 2007. Acceptability of A-CASI by HIV-positive IDUs in a multisite, randomized, controlled trial of behavioral intervention (INSPIRE). J. Acquir. Immune Defic. Syndr. 46 (Suppl. 2), S48-S54.
32. Palepu A., Tyndall M.W., Joy R., Kerr T., Wood E., Press N., Hogg R.S., Montaner J.S. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006, 84:188-194.
33. Rigsby M.O., Rosen M.I., Beauvais J.E., Cramer J.A., Rainey P.M., O'Malley S.S., Dieckhaus K.D., Rounsaville B.J. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J. Gen. Intern. Med. 2000, 15:841-847.
34. Sambamoorthi U., Warner L.A., Crystal S., Walkup J. Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug Alcohol Depend. 2000, 60:77-89.
35. Saunders J.B., Aasland O.G., Babor T.F., Fuente J.R., Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993, 88:791-804.
36. Sharpe T.T., Lee L.M., Nakashima A.K., Elam-Evans L.D., Fleming P.L. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J. Commun. Health 2004, 29:117-127.
37. Simoni J.M., Kurth A.E., Pearson C.R., Pantalone D.W., Merrill J.O., Frick P.A. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006, 10:227-245.
38. Stein M.D., Rich J.D., Maksad J., Chen M.H., Hu P., Sobota M., Clarke J. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am. J. Drug Alcohol Abuse 2000, 26:195-205.
39. Steinbauer J.R., Cantor S.B., Holzer C.E., Volk R.J. Ethnic and sex bias in primary care screening tests for alcohol use disorders. Ann. Intern. Med. 1998, 129:353-362.
40. Strain E.C., Bigelow G.E., Liebson I.A., Stitzer M.L. Moderate- vs high-dose methadone in the treatment of opioid dependence. JAMA 1999, 281:1000-1005.
41. Uhlmann S., Milloy M.J., Kerr T., Zhang R., Guillemi S., Marsh D., Hogg R.S., Montaner J.S., Wood E. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010, 105:907-913.